Oncogenic pathways as the basis of primary immune ignorance

Area of Science:

• Oncology
• Immunology
• Cancer Biology

Background:

• Immune checkpoint inhibitor therapies (ICTs) have transformed cancer care, offering durable responses in some patients.
• However, many patients, even with immunogenic tumors like melanoma and non-small cell lung cancer, do not benefit from single-agent ICT.
• Low response rates are also observed in breast, colon, and prostate cancers, suggesting a broader issue of primary immune ignorance.

Purpose of the Study:

• This review investigates the molecular mechanisms underlying the primary immune-ignorant tumor phenotype.
• It focuses on how oncogenic pathways contribute to the development of tumors that are unresponsive to single-agent ICTs.

Main Methods:

• This is a review article, synthesizing existing research on tumor immunology and oncogenic pathways.
• It examines the literature concerning the molecular basis of immune ignorance in various cancer types.

Main Results:

• A significant body of evidence suggests most tumors are primarily immune-ignorant, explaining limited responses to ICTs.
• Oncogenic pathways play a crucial role in establishing and maintaining this immune-ignorant state.

Conclusions:

• Understanding how oncogenic pathways create immune-ignorant tumors is critical for improving ICT efficacy.
• Targeting these pathways may overcome primary resistance and expand the benefits of immunotherapy to more cancer patients.